Meet Siti Nurmaini, Developer of TeleOTIVA for Cervical Cancer Screening
Siti Nurmaini has been named among the top three candidates in the Health Technology Innovator category of the 2026 DPD RI Awards. She conceived and developed TeleOTIVA, an artificial intelligence (AI) and telemedicine-based cervical cancer screening innovation designed to make healthcare services more accessible across Indonesia.
The 2026 DPD RI Awards’ top three candidates were selected at the first meeting of the judging panel at Menara Bank Mega in South Jakarta on Monday (5 October 2026). Several panel members attended in person, while those unable to attend still provided their views and contributed to the discussion.
The 2026 DPD Awards expert panel comprises Culture Minister Fadli Zon; National Research and Innovation Agency (BRIN) Head Arif Satria; Deputy Chair of the House of Representatives’ Commission II Dede Yusuf Macan Effendi; Regional Representative Council (DPD RI) member Agustin Teras Narang; and University of Indonesia (UI) Faculty of Mathematics and Natural Sciences professor Agustino Zulys.
The 2026 DPD RI Awards has four categories: Innovator in Non-Formal Education/Out-of-School Education, Health Technology Innovator, Independent Food-Secure Village Advocate, and Regional Culture Preserver.
Siti Nurmaini’s profile
Siti Nurmaini is a professor at Sriwijaya University (Unsri), and has been developing TeleOTIVA since 2020. TeleOTIVA is a digital health innovation integrating AI, computer vision and telemedicine to support cervical cancer screening and early detection.
The TeleOTIVA application is available on the App Store and Google Play. Siti said it helps healthcare workers document cervical images, identify cervical areas and suspected lesions, and access supporting information for clinical evaluation and decision-making.
Through its telemedicine feature, examination results can be discussed with medical professionals or specialist doctors regardless of distance. This supports services at community health centres (puskesmas) and in areas with limited access to specialists. TeleOTIVA also enables digital recording of examinations and results, as well as monitoring of patient follow-up.
The innovation aims to improve access, consistency and efficiency, and to make cervical cancer screening services more equitable, particularly for people in areas with limited healthcare access.
TeleOTIVA is designed as a clinical decision-support system, not as a replacement for medical professionals. It has the potential to be implemented and developed across a wider network of healthcare facilities in Indonesia. Siti said it had already made a tangible contribution to expanding access to AI- and telemedicine-based screening for precancerous cervical lesions.
To date, TeleOTIVA has screened more than 2,000 subjects and involved over 50 medical professionals and specialist doctors. Its model has achieved 98.14 per cent accuracy, 95.65 per cent sensitivity and 98.82 per cent specificity.
Siti said TeleOTIVA has an intellectual property portfolio. Commercialisation of the innovation was further advanced through a patent licensing agreement with PT INTI Konten Indonesia (INTENS) in 2026.
Siti said TeleOTIVA’s development had generated a range of scientific publications, including research in Informatics in Medicine Unlocked, IEEE Access, Scientific Reports and Sensors, covering detection, segmentation, interpretation and AI development for cervical screening.
For Siti, these achievements strengthen TeleOTIVA’s position as a research-based innovation that is protected by intellectual property, commercialised and delivering a direct impact on public healthcare services.
Source: jawawa.id (https://jawawa.id/newsitem/meet-siti-nurmaini-developer-of-teleotiva-for-cervical-cancer-screening-1792741957)
Originally published by detikcom (https://news.detik.com/berita/d-8720555/mengenal-siti-nurmaini-kembangkan-teleotiva-untuk-skrining-kanker-serviks), translated from Indonesian